(-)-Fadrozole, with the CAS number 102676-86-8, is a selective aromatase inhibitor primarily used in the treatment of hormone-dependent conditions, such as breast cancer. It is characterized by its ability to inhibit the aromatase enzyme, which is responsible for converting androgens into estrogens, thereby reducing estrogen levels in the body. This property makes it particularly valuable in managing estrogen-sensitive tumors. The compound is typically presented as a white to off-white crystalline solid and is soluble in organic solvents. Its chemical structure features a triazole ring, which is integral to its mechanism of action. (-)-Fadrozole has been studied for its pharmacokinetics, demonstrating a favorable profile with a relatively long half-life, allowing for once-daily dosing. Additionally, it exhibits a good safety profile, although potential side effects may include hot flashes, fatigue, and joint pain, which are common in aromatase inhibitors. Overall, (-)-Fadrozole represents an important therapeutic option in oncology, particularly for postmenopausal women with estrogen receptor-positive breast cancer.

(-)-Fadrozole

102676-86-8: (-)-Fadrozole, with the CAS number 102676-86-8, is a selective aromatase inhibitor primarily used in the treatment of hormone-dependent conditions, such as breast cancer. It is characterized by its ability to inhibit the aromatase enzyme, which is responsible for converting androgens into estrogens, thereby reducing estrogen levels in the body. This property makes it particularly valuable in managing estrogen-sensitive tumors. The compound is typically presented as a white to off-white crystalline solid and is soluble in organic solvents. Its chemical structure features a triazole ring, which is integral to its mechanism of action. (-)-Fadrozole has been studied for its pharmacokinetics, demonstrating a favorable profile with a relatively long half-life, allowing for once-daily dosing. Additionally, it exhibits a good safety profile, although potential side effects may include hot flashes, fatigue, and joint pain, which are common in aromatase inhibitors. Overall, (-)-Fadrozole represents an important therapeutic option in oncology, particularly for postmenopausal women with estrogen receptor-positive breast cancer.

4-[(5S)-5H,6H,7H,8H-imidazo[1,5-a]pyridin-5-yl]benzonitrile

(S)-Dexfadrostat ((S)-Fadrozole), an aromatase inhibitor, exhibits an IC 50 of 4.6 nM in in vitro assays using human placental microsomes. It is applicable for research on estrogen-dependent breast cancer, gynecomastia, and systemic lupus erythematosus.

CAS 102676-86-8

(-)-Fadrozole

4-[(5S)-5H,6H,7H,8H-imidazo[1,5-a]pyridin-5-yl]benzonitrile

Ref: IN-DA00082L

(S)-Dexfadrostat

Ref: TM-T200084